Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q3 FY25 results · Oct–Dec 2024
Procter & Gamble Health reported revenue from operations of ₹309.77 crore (down 0.1% from Q3 FY24) and net profit of ₹90.90 crore (up 26.1% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a standalone basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 309.77 | 309.97 | −0.1% | 313.41 | −1.2% |
| Other income | 3.96 | 5.18 | −23.6% | 3.28 | +20.7% |
| Total income | 313.73 | 315.15 | −0.5% | 316.69 | −0.9% |
| Profit before tax | 121.69 | 99.72 | +22.0% | 111.40 | +9.2% |
| Net profit for the period | 90.90 | 72.07 | +26.1% | 82.33 | +10.4% |
| EPS, basic (₹) | 54.76 | 43.40 | +26.2% | 49.60 | +10.4% |
| Net margin (%) | 29.3 | 23.3 | 26.3 |
Standalone
- Filed with BSE
- 12 Feb 2025, 20:00 IST
- Board meeting
- 12 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE